JP6283030B2 - 高度に多様なコンビナトリアル抗体ライブラリ - Google Patents
高度に多様なコンビナトリアル抗体ライブラリ Download PDFInfo
- Publication number
- JP6283030B2 JP6283030B2 JP2015529046A JP2015529046A JP6283030B2 JP 6283030 B2 JP6283030 B2 JP 6283030B2 JP 2015529046 A JP2015529046 A JP 2015529046A JP 2015529046 A JP2015529046 A JP 2015529046A JP 6283030 B2 JP6283030 B2 JP 6283030B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- library
- human
- camel
- families
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282836 Camelus dromedarius Species 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 13
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 10
- 241000282842 Lama glama Species 0.000 claims description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 210000004602 germ cell Anatomy 0.000 description 21
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241001416177 Vicugna pacos Species 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 241000282828 Camelus bactrianus Species 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000282832 Camelidae Species 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241001244729 Apalis Species 0.000 description 1
- 208000000023 Bland White Garland Syndrome Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 201000004804 anomalous left coronary artery from the pulmonary artery Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010060686 dual specificity phosphatase 12 Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695819P | 2012-08-31 | 2012-08-31 | |
| US61/695,819 | 2012-08-31 | ||
| PCT/EP2013/068110 WO2014033304A2 (en) | 2012-08-31 | 2013-09-02 | Highly diverse combinatorial antibody libraries |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526495A JP2015526495A (ja) | 2015-09-10 |
| JP6283030B2 true JP6283030B2 (ja) | 2018-02-21 |
Family
ID=49117845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015529046A Active JP6283030B2 (ja) | 2012-08-31 | 2013-09-02 | 高度に多様なコンビナトリアル抗体ライブラリ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10040870B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2890709A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6283030B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104583236A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013310839B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2879834A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL236524B (cg-RX-API-DMAC7.html) |
| IN (1) | IN2015DN00138A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014033304A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| HUE072731T2 (hu) | 2016-05-20 | 2025-12-28 | Harpoon Therapeutics Inc | Egyszeres láncú variábilis fragmentumú CD3-kötõ proteinek |
| AU2017268460B2 (en) | 2016-05-20 | 2023-12-14 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| KR20210087108A (ko) | 2016-11-23 | 2021-07-09 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| CN110139952B (zh) * | 2016-12-09 | 2022-11-25 | 深圳华大生命科学研究院 | 骆驼科抗体可变区免疫组库构建的引物组合及应用 |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
| WO2018209298A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| LT3694529T (lt) | 2017-10-13 | 2024-10-10 | Harpoon Therapeutics, Inc. | Trispecifiniai baltymai ir panaudojimo būdai |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| JP2021523192A (ja) | 2018-05-14 | 2021-09-02 | ハープーン セラピューティクス，インク． | 免疫グロブリン分子の条件的活性化のための結合部分 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| CA2762837C (en) * | 2009-05-20 | 2021-08-03 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| GB2476681B (en) * | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
-
2013
- 2013-09-02 CN CN201380044638.9A patent/CN104583236A/zh active Pending
- 2013-09-02 US US14/419,881 patent/US10040870B2/en active Active
- 2013-09-02 AU AU2013310839A patent/AU2013310839B2/en active Active
- 2013-09-02 CA CA2879834A patent/CA2879834A1/en not_active Abandoned
- 2013-09-02 EP EP13758830.7A patent/EP2890709A2/en not_active Withdrawn
- 2013-09-02 JP JP2015529046A patent/JP6283030B2/ja active Active
- 2013-09-02 WO PCT/EP2013/068110 patent/WO2014033304A2/en not_active Ceased
- 2013-09-02 IN IN138DEN2015 patent/IN2015DN00138A/en unknown
-
2014
- 2014-12-31 IL IL236524A patent/IL236524B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN00138A (cg-RX-API-DMAC7.html) | 2015-06-12 |
| US20150166680A1 (en) | 2015-06-18 |
| AU2013310839B2 (en) | 2017-06-01 |
| IL236524B (en) | 2019-01-31 |
| CN104583236A (zh) | 2015-04-29 |
| JP2015526495A (ja) | 2015-09-10 |
| US10040870B2 (en) | 2018-08-07 |
| AU2013310839A1 (en) | 2015-01-29 |
| CA2879834A1 (en) | 2014-03-06 |
| WO2014033304A3 (en) | 2014-05-01 |
| EP2890709A2 (en) | 2015-07-08 |
| WO2014033304A2 (en) | 2014-03-06 |
| IL236524A0 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6283030B2 (ja) | 高度に多様なコンビナトリアル抗体ライブラリ | |
| Zhai et al. | Synthetic antibodies designed on natural sequence landscapes | |
| Chiu et al. | Engineering antibody therapeutics | |
| Mathonet et al. | The application of next generation sequencing to the understanding of antibody repertoires | |
| US20200308256A1 (en) | Antibody phage display library | |
| JP7086856B2 (ja) | 免疫レパートリー発掘 | |
| JP7332691B2 (ja) | 抗体の開発可能性が最大化された抗体ライブラリー | |
| Erasmus et al. | A single donor is sufficient to produce a highly functional in vitro antibody library | |
| US12258679B2 (en) | Polyclonal mixtures of antibodies, and methods of making and using them | |
| Larsen et al. | Next‐generation approaches to advancing eco‐immunogenomic research in critically endangered primates | |
| Hamidon et al. | Immune TB antibody phage display library as a tool to study B cell immunity in TB infections | |
| JP2019068837A (ja) | 標的分子に結合するポリペプチドの決定方法及び決定システム | |
| Nathan et al. | Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin | |
| Pohl et al. | Considerations for using phage display technology in therapeutic antibody drug discovery | |
| WO2021247761A1 (en) | Methods and compositions for in vitro affinity maturation of monoclonal antibodies | |
| Gueneau et al. | Round optimization for improved discovery of native bispecific antibodies | |
| Sun et al. | Degenerate primer design to clone the human repertoire of immunoglobulin heavy chain variable regions | |
| Leow et al. | Monoclonal IgY antibodies | |
| Valdés-Alemán et al. | Hybridization-based antibody cDNA recovery for the production of recombinant antibodies identified by repertoire sequencing | |
| Lai et al. | Synthetic Antibody Engineering: Concepts and Applications | |
| Ford | Uncovering the hidden diversity of antibody heavy chains and their implications for autoantibody mediated disease. | |
| 유덕균 | Prediction of antigen binding reactivity using supervised learning on clonal enrichment pattern through bio-panning | |
| Martin | Generation of Antibodies in Agricultural Species Using Classical and Novel Platforms | |
| Ehling | Synthetic selection and engineering of antibodies | |
| Bhatt et al. | Technologies for the generation of human antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150413 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170825 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170825 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180125 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6283030 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |